Droia Ventures

Foundation date





Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in novel science and innovative approaches to bring promising drug candidates to patients, and accelerate their progress by actively supporting young drug development companies to achieve clinical proof of concept with their lead programs. We have an in-house team of experts and drug development professionals who follow our companies closely and provide hands-on support.

Droia invests in early financing rounds and also incubates new companies. Operating from Luxembourg and Belgium, Droia invests globally.

Upcoming events

Latest news

  • argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia

    21 hours ago

  • Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion

    Wednesday November 22nd 2023

  • argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis

    Thursday November 16th 2023